This narrative review aims to synthesize current advances, explore future directions, and highlight outstanding challenges in the application of Artificial Intelligence to PET imaging for the clinical management of Alzheimer’s disease, with particular focus on three key modalities: 18F-FDG PET, Amyloid PET, and Tau PET. The gene discussed is MAPT; the disease is Alzheimer disease.